Printer Friendly

Point Therapeutics Announces Preclinical Data Presentations at Upcoming American Association of Cancer Research Annual Meeting.

BOSTON -- Point Therapeutics, Inc. (NASDAQ: POTP) today reported the upcoming presentation of preclinical data at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) taking place in Los Angeles, California, April 14-18, 2007. The AACR poster presentations report on preclinical studies on talabostat's novel mechanism of action.

Additional details for the AACR presentations are as follows:

Presentation Date and Time: Monday, April 16, 2007, 8:00 AM -12:00 PM PT

Abstract #1894: Immune mechanisms of action of talabostat: a dipeptidyl peptidase targeted anti-tumor agent

Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM -12:00 PM PT

Abstract #5622: The anti-tumor potential of inhibitors of the DASH proteases in a mouse model of human breast cancer

The posters associated with the abstracts will be available on the Point Therapeutics' web site at immediately following their presentation.

About Point Therapeutics, Inc.:

Point is a Boston-based biopharmaceutical company currently studying its lead product candidate, talabostat, in two Phase 3 double blind, placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 13, 2007
Previous Article:Universal Display Corporation and Nippon Steel Chemical Company Announce OLED Performance Enhancements at FINETECH JAPAN.
Next Article:Chesapeake Energy Corporation Announces 2007 First Quarter Financial and Operational Results Release Date and Conference Call Information.

Related Articles
Callisto Details Clinical Research Progress on Proprietary Anti-Cancer Drugs and Strategic Initiatives for 2006; Expected Start of Pediatric Trial of...
Cyclacel to Present Preclinical Data on Lead Clinical-Stage Drug, Seliciclib, at American Association for Cancer Research Annual Meeting.
New Preclinical Data Supports Role of Talabostat in Enhancing Immune Functions and Promoting The Body's Natural Ability to Fight Cancer; Point...
New Data Supports Talabostat's Ability to Stimulate Key Cytokines Essential to Immunostimulation; Point Therapeutics, Inc. Presents at the 2006 AACR...
AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR.
Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting.
Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting.
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer.
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR.
Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters